Protocol Ledger

NCT04211909 · Phase III · COMPLETED

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Vir

Interventional Phase III clinical trial protocol NCT04211909 sponsored by Gilead Sciences in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-01-03 Enrollment: 87 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04211909
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)87 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04211909
Protocol FieldVerified Registry Value
NCT IdentifierNCT04211909
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment87 participants (ACTUAL)
Registered Start Date2020-01-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04211909
Hospital Research SiteLocationSite Profile
Seoul National University Bundang HospitalSeongnam-si, South KoreaOpen Hospital Dossier ->
Dong-A University HospitalBusan, South KoreaOpen Hospital Dossier ->
Pusan National University HospitalBusan, South KoreaOpen Hospital Dossier ->
Kyungpook National University HospitalDaegu, South KoreaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI